Physicians' Academy for Cardiovascular Education

Treatment goals for LDL-c-lowering and emerging evidence for the importance of Lp(a)

10' education - May 26, 2020 - Prof. Wouter Jukema, MD - Leiden, The Netherlands

Reduction of revascularization with icosapent ethyl in patients with hypertriglyceridemia

3' education - May 25, 2020 - Benjamin Peterson, MD

Increase in out-of-hospital cardiac arrest during the COVID-19 outbreak in Lombardy, Italy

3' education - May 8, 2020 - Enrico Baldi, MD

Venous thromboembolism in COVID-19 patients

5' education - May 6, 2020 - Prof. Saskia Middeldorp

Obesity as a risk factor for severity of COVID-19: multiple potential mechanisms

5' education - May 1, 2020 - Prof. Naveed Sattar, MD

COVID-19 associated thrombotic complications

5' education - Apr. 22, 2020 - Erik Klok, MD, PhD
Lecture 1 out of 3

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD
Lecture 2 out of 3

A clinical perspective on COVID-19, ACE2 and RAAS inhibition

10' education - Apr. 18, 2020 - Prof. Murray Epstein, MD
Lecture (panel discussion) 3 out of 3

COVID-19, ACE2 and RAAS inhibition: What are the implications for practice?

10' education - Apr. 17, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

One step closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 9, 2020 - Dirk Blom, PhD

Use of ARNI in HFpEF patients reduces NT-proBNP levels

3' education - Apr. 8, 2020 - Jonathan Cunningham, MD

Reduced bleeding with P2Y12i monotherapy after 3 months DAPT after complex PCI

3' education - Apr. 7, 2020 - Prof. George Dangas, MD, PhD - ACC 2020

Stopping with aspirin after 3 months DAPT is safe in a wide range of patients

3' education - Apr. 2, 2020 - Prof. Freek Verheugt, MD

Mechanistic underpinning of CV benefit observed with icosapent ethyl

3' education - Apr. 2, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

Remarkable reduction of LDL-c with antibody against angiopoietin-like protein 3 in HoFH

3' education - Apr. 1, 2020 - Prof. Frederick Raal, PhD - ACC 2020

Higher rate of smoking cessation with e-cigarettes compared to counseling

3' education - Apr. 1, 2020 - Prof. Mark Eisenberg, MD - ACC 2020

Added value of sGC stimulator in worsening HFrEF patients

3' education - Mar. 31, 2020 - Prof. Paul Armstrong, MD - ACC 2020

CAPACITY COVID: a registry of CV variables in patients with COVID-19

3' education - Mar. 31, 2020 - Prof. Folkert Asselbergs, MD, PhD

Oral anticoagulant monotherapy reduces bleeding in AF patients after TAVI

3' education - Mar. 30, 2020 - Dr. Jur ten Berg, MD, PhD - ACC 2020

NOAC plus aspirin superior to aspirin alone for preventing major adverse limb and CV events

3' education - Mar. 29, 2020 - Dr. Marc P. Bonaca, MD - ACC 2020

PCSK9i reduces CV events in patients with recent MI

Literature - May 28, 2020 - Gencer B, Mach F, Murphy SA et al., - JAMA Cardiol. 2020.

Patients with recent MI were at higher risk of CV events and tended to have greater ARRs with evolocumab compared to those with remote MIs, as shown in this secondary analysis of the FOURIER trial.

Use of in-hospital anticoagulation and mortality in hospitalized COVID-19 patients

Literature - May 27, 2020 - Paranjpe I, et al. - J Am Coll Cardiol 2020

Survival was examined in a cohort of hospitalized COVID-19 patients in New York City, who were divided in those who received anticoagulation during hospital stay and those who did not.

Treatment goals for LDL-c-lowering and emerging evidence for the importance of Lp(a)

10' education - May 26, 2020 - Prof. Wouter Jukema, MD - Leiden, The Netherlands
Prof. Jukema explains the main principles for LDL-c-lowering therapy as described in the 2019 ESC/EAS guidelines and discusses results from several trials that investigated the role of Lp(a) on CV outcomes.

Prof. Jukema explains the main principles for LDL-c-lowering therapy as described in the 2019 ESC/EAS guidelines and discusses results from several trials that investigated the effect of Lp(a) on CV outcomes.

High incidence of acute kidney injury in hospitalized patients with COVID-19

Literature - May 26, 2020 - Hirsch JS et al., - Kidney Int. 2020.

This study showed that 36.3% of patients hospitalized with COVID-19 developed acute kidney injury during hospitalization.

FDA Fast Track designation for novel selective cardiac myosin activator in HF

News - May 26, 2020

Omecamtiv mecarbil, a cardiac myosin activator or cardiac myotrope, has been granted Fast Track designation by the FDA for treatment of HFrEF patients.

Three studies show no harm of ARBs/ACEi in COVID-19 patients

News - May 26, 2020

Recently, three papers were published in the N Engl J Med on the effect of ACE inhibitors and ARBs in patients with COVID-19. All three studies showed no evidence that ACE inhibitors or ARBs affect the risk of COVID-19.

Reduction of revascularization with icosapent ethyl in patients with hypertriglyceridemia

3' education - May 25, 2020 - Benjamin Peterson, MD
REDUCE-IT REVASC evaluated the effect of icosapent ethyl on revascularizations in patients with high triglyceride levels, who had CVD or diabetes with at least one additional CV risk factor.

Benjamin Peterson gives a brief presentation of the results of the REDUCE-IT REVASC study, which evaluated the effect of icosapent ethyl on first and total revascularizations in patients with hypertriglyceridemia.

PCSK9 inhibitor reduces MI risk across multiple MI subtypes and sizes

Literature - May 25, 2020 - Wiviott SD et al., - JAMA Cardiol. 2020.

The PCSK9 inhibitor evolocumab significantly reduced risk of MI across multiple MI subtypes and sizes, as shown by an analysis of the FOURIER trial.

Icosapent ethyl reduces coronary revascularization

News - May 20, 2020
Administration of 4 g/day icosapent ethyl reduced first coronary revascularizations by 34% compared to placebo in patients with elevated triglyceride levels, who had CVD or diabetes with additional CV risk factors.

Administration of 4 g/day icosapent ethyl reduced first coronary revascularizations by 34% compared to placebo in patients with elevated triglyceride levels, who had CVD or diabetes with additional CV risk factors.

Practical recommendations for management of diabetes during COVID-19 pandemic

News - May 19, 2020

A consensus document by a group of representatives from primary and secondary care has been published on the management of diabetes for patients at risk or with confirmed COVID-19.

Coagulopathy in patients with COVID-19

Literature - May 19, 2020 - Levi M et al., - Lancet Haematol. 2020.

This comment article describes characteristics of coagulopathy in patients with COVID-19 and discusses recommendations for the therapeutic management of COVID-19-associated coagulopathy.

Drinking filtered coffee associated with lower mortality

Literature - May 18, 2020 - Tverdal A et al., - Eur J Prev Cardiol. 2020.

A large Norwegian cohort study showed that drinking filtered coffee was associated with lower mortality than no coffee, while no association between coffee drinking and mortality was observed for those drinking unfiltered coffee.